Canada markets closed
  • S&P/TSX

    20,402.66
    -59.27 (-0.29%)
     
  • S&P 500

    4,455.48
    +6.50 (+0.15%)
     
  • DOW

    34,798.00
    +33.18 (+0.10%)
     
  • CAD/USD

    0.7904
    +0.0001 (+0.02%)
     
  • CRUDE OIL

    73.95
    +0.65 (+0.89%)
     
  • BTC-CAD

    54,765.89
    +608.66 (+1.12%)
     
  • CMC Crypto 200

    1,067.20
    -35.86 (-3.25%)
     
  • GOLD FUTURES

    1,750.60
    +0.80 (+0.05%)
     
  • RUSSELL 2000

    2,248.07
    -10.97 (-0.49%)
     
  • 10-Yr Bond

    1.4600
    +0.0500 (+3.55%)
     
  • NASDAQ

    15,047.70
    -4.54 (-0.03%)
     
  • VOLATILITY

    17.75
    -0.88 (-4.72%)
     
  • FTSE

    7,051.48
    -26.87 (-0.38%)
     
  • NIKKEI 225

    30,248.81
    +609.41 (+2.06%)
     
  • CAD/EUR

    0.6737
    +0.0010 (+0.15%)
     

Combining AstraZeneca and mRNA COVID-19 vaccines is effective -Danish study

·1 min read

COPENHAGEN (Reuters) - Combining AstraZeneca's COVID-19 vaccine with a second dose from either Pfizer-BioNTech or Moderna's jab provides "good protection", Denmark's State Serum Institute said on Monday. 

  A growing number of countries are looking at switching to different COVID-19 vaccines for second doses, a measure particularly necessary in Denmark after health authorities discontinued inoculations with AstraZeneca's vaccine in April over rare side-effect concerns. 

  More than 144,000 Danes, mostly frontline personnel in the health sector and the elderly, received their first jab with AstraZeneca's vaccine but were subsequently vaccinated with either Pfizer-BioNTech or Moderna's shots. 

  "The study shows that fourteen days after a combined vaccination program, the risk of infection with SARS-CoV-2 is reduced by 88% compared to unvaccinated individuals," the State Serum Institute (SSI) said. 

  That is a "high efficacy", SSI added, comparable to the 90% efficacy rate of two doses from Pfizer-BioNTech's vaccine, confirmed in a different Danish study. 

  The study, published last week, covered a span of more than five months between February and June this year, a period in which the Alpha-variant of the coronavirus was predominant. 

  It could not conclude whether the same protection applied to the Delta-variant, which is now the most widespread in Denmark. 

  It also provided no efficacy data on COVID-19 related deaths or hospitalisations, since none took place following the combined vaccination programme. 

  (Reporting by Nikolaj Skydsgaard, editing by Louise Heavens) 

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting